(NHS) Neuberger Berman High Yield - Overview
Fund: Bonds, Debt, Credit, Income
Dividends
| Dividend Yield | 14.65% |
| Yield on Cost 5y | 16.75% |
| Yield CAGR 5y | -2.11% |
| Payout Consistency | 92.8% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 10.4% |
| Relative Tail Risk | -7.11% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.61 |
| Alpha | 4.55 |
| Character TTM | |
|---|---|
| Beta | 0.341 |
| Beta Downside | 0.499 |
| Drawdowns 3y | |
|---|---|
| Max DD | 18.17% |
| CAGR/Max DD | 0.44 |
Description: NHS Neuberger Berman High Yield January 02, 2026
Neuberger Berman High Yield Strategies (NYSE MKT:NHS) is a U.S.-based mutual fund that focuses on high-yield corporate bonds, positioning itself as a pure “high yield” credit vehicle within the broader fixed-income space.
As of the most recent quarterly filing, the fund manages roughly $4.2 billion in assets, with a weighted-average maturity of about 5.8 years and a current weighted-average yield near 7.1 %. Its portfolio is tilted toward lower-rated issuers (average credit rating around BB), and the expense ratio sits at 0.78 %. Performance has historically tracked the Bloomberg Barclays U.S. Corporate High-Yield Index, but recent widening of credit spreads-driven by higher Fed rates and lingering recession concerns-has added volatility to returns.
For a deeper, data-driven look at NHS’s risk-adjusted metrics and how it stacks up against peers, you might explore the fund’s profile on ValueRay.
What is the price of NHS shares?
Over the past week, the price has changed by -0.13%, over one month by +2.59%, over three months by +5.60% and over the past year by +12.58%.
Is NHS a buy, sell or hold?
What are the forecasts/targets for the NHS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 8.9 | 16.7% |
NHS Fundamental Data Overview February 05, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 206.5m USD (206.5m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 206.5m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 206.5m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 7.17% (E(206.5m)/V(206.5m) * Re(7.17%) + (debt-free company))
Discount Rate = 7.17% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)